(-)-CannabidiolCat. No. 1570 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: CBD Chemical Name: 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol |
Biological Activity
Non-psychotropic constituent of cannabis that is anticonvulsive, antihyperalgesic and neuroprotective in vivo. GPR55 and weak CB1 antagonist (IC50 values are 0.445 and 3.35 μM), CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50 = 27.5 μM). Also a weak agonist at VR1 vanilloid receptors (EC50 = 3.5 μM).Certificate of Analysis / Safety Data Sheet
References
Petitet et al (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63 PL1. PMID: 9667767.
Costa et al (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br.J.Pharmacol. 143 247. PMID: 15313881.
Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID: 17876302.
Thomas et al (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br.J.Pharmacol. 150 613. PMID: 17245363.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: (-)-Cannabidiol, supplier, Natural, cannabinoids, AMT, inhibitors, GPR55, antagonists, weak, CB1, CB2, inverse, agonists, Anandamide, Transporters, Monoamine, Neurotransmitter, Non-Selective, Receptors, cb2r, cb1r
Quick Order
Find multiple products by catalog number
New Products in this Area
Potent, high affinity CB1 receptor inverse agonist
SR 141716ASelective CB1 receptor antagonist
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK





